Cardio3 BioSciences Announces Intention to Conduct a

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Cardio3 BioSciences Announces Intention to Conduct a Registered Public Offering in the United States

MONT-SAINT-GUIBERT, Belgium, March 31, 2015 (GLOBE NEWSWIRE) -- Cardio3 BioSciences (C3BS) (Brussels: CARD ) (Paris: CARD ), a leader in engineered cell therapies with clinical programs initially targeting indications in cardiovascular disease and oncology, today announced its intention to conduct a registered public offering in the United States. The timing, number of shares and price of the proposed offering have not yet been determined.

A draft registration statement relating to these securities has been confidentially submitted to the U.S. Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement has been publicly filed and has become effective.

This announcement is being made pursuant to and in accordance with Rule 135 under the Securities Act of 1933. As required by Rule 135, this press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

For more information, please contact:  
   
Cardio3 BioSciences www.c3bs.com
Christian Homsy, CEO Tel: +32 10 39 41 00
Julie Grade, Corporate Communications Manager jgrade@c3bs.com
For Europe: Consilium Strategic Communications  Tel : +44 20 3709 5700
Amber Bielecka, Chris Welsh, Laura Thornton  cardio3@consilium-comms.com
For the U.S: The Ruth Group Tel: +1 646 536 7012 / 7014
Lee Roth (Investors), Kirsten Thomas (Media) lroth@theruthgroup.com 
  kthomas@theruthgroup.com

To subscribe to Cardio3 BioSciences' newsletter, visit www.c3bs.com .

Follow us on Twitter @Cardio3Bio .

About Cardio3 BioSciences

Cardio3 BioSciences is a leader in engineered cell therapy with clinical programs initially targeting indications in cardiovascular disease and oncology. Founded in 2007 and based in the Walloon region of Belgium, Cardio3 BioSciences leverages research collaborations in the USA with the Mayo Clinic (MN, USA) and Dartmouth College (NH, USA). The Company's lead product candidate in cardiology is C-Cure®, an autologous stem cell therapy for the treatment of ischemic heart failure. The Company's lead product candidate in oncology is CAR-NKG2D, an autologous CAR T-cell product candidate using NKG2D, a natural killer cell receptor designed to target ligands present on multiple tumor types, including ovarian, bladder, breast, lung and liver cancers, as well as leukemia, lymphoma and myeloma. Cardio3 BioSciences is also developing medical devices for enhancing the delivery of diagnostic and therapeutic agents into the heart (C-Cath ez ®) and potentially for the treatment of mitral valve defects.

Cardio3 BioSciences' shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CARD.

To learn more about Cardio3 BioSciences, please visit www.c3bs.com

Forward looking statements

In addition to historical facts or statements of current condition, this press release contains forward-looking statements, which reflect our current expectations and projections about future events, including statements concerning the potential registered initial public offering, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including timely submission and approval of anticipated regulatory filings; the successful initiation and completion of clinical trials, including Phase III clinical trials for C-Cure® and Phase I clinical trial for CAR-NKG2D additional clinical results validating the use of adult autologous stem cells to treat heart failure and CAR T-cell autologous therapy to treat cancer; satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; obtaining, maintaining and protecting intellectual property, our ability to enforce our patents against infringers and defend our patent portfolio against challenges from third parties, competition from others developing products for similar uses, our ability to manage operating expenses, and our ability to obtain additional funding to support our business activities and establish and maintain strategic business alliances and new business initiatives. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements.

C-Cure, CAR-NKG2D, C-Cath ez , OnCyte, Cardio3 BioSciences and the Cardio3 BioSciences, C-Cath ez , CHART-1, CHART-2 and OnCyte logos are trademarks or registered trademarks of Cardio3 BioSciences SA, in Belgium, other countries, or both. Mayo Clinic holds equity in Cardio3 BioSciences as a result of intellectual property licensed to the company.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Prospera’s DFW Culture Win Matters Beyond the Plaque

Updated Category News Views 46

Employee survey ballots rarely make pulses race, but this one deserves more than a lazy shrug. Prospera Financial Services has landed on The Dallas Morning News’ 2026 Top Workplaces DFW list for a second consecutive year, placing in the Top Small Workplaces category. For a boutique independent broker-dealer, that is not meaningless wall décor. The people doing the...

Continue Reading
Subsplash Builds a Broader Church Software Stack in 2026

Updated Category News Views 113

Church software has spent too many years behaving like a junk drawer, and Subsplash is plainly trying to replace it with one working system. The company used its November 18 Product Event in Dallas to show off releases from 2026 and preview two additions: Communications, due in December, and Subsplash Intelligence, targeted for early 2027. A Serious Push Beyond the Church...

Continue Reading
D-Wave Investors Face December 15 Lead Plaintiff Clock

Updated Category News Views 94

Quantum dreams met a very earthly spreadsheet problem at D-Wave this summer. The proposed securities class action against D-Wave Quantum Inc. puts a hard date on the issue for investors who bought shares between February 26 and August 25, 2026: December 15, 2026 is the deadline to seek lead-plaintiff status. That does not mean every holder needs to march into court. It...

Continue Reading
Six LIFE Photographers Bring History Into Florida Focus

Updated Category News Views 55

Seventy photographs can make a pretty loud argument when the historical record has been this lopsided. The Ashley Gibson Barnett Museum of Art at Florida Southern College has brought LIFE: Six Women Photographers to Lakeland, and it deserves more than the usual polite nod given to a traveling museum show. Open since November 14, 2026, and running through March 7, 2027,...

Continue Reading
Wenge AI Removes a Small Friction Point for ScienceOra

Updated Category News Views 84

Scientific software rarely loses users because the underlying model is too clever; it loses them because getting through the front door is a nuisance. Wenge AI has addressed that unglamorous problem by adding Google and Apple sign-in options to the international version of ScienceOra, its AI-powered research and decision-support platform. This is not the sort of...

Continue Reading
CITGO Sign Return Caps Kenmore's Careful Rebuild Work

Updated Category News Views 62

Thirty feet upward and 120 feet eastward is not the sort of move that usually stops a city in its tracks, yet Boston’s CITGO Sign was never merely rooftop hardware. Its public relighting in Kenmore Square marks the final phase of the redevelopment at 660 Beacon Street, and the real accomplishment is less flashy than the lights: a beloved, federally landmarked object...

Continue Reading
APEC's Shenzhen Signal Is Bigger Than a Two-Day Summit

Updated Category News Views 72

Shenzhen spent two days trying to turn regional anxiety into a workable agenda. The APEC CEO Summit 2026, held November 17 and 18 at the Qianhai International Convention Center, brought together more than 2,000 political and business leaders from all 21 APEC economies and 13 economies outside the group. That is a serious room, not a ceremonial photo line. Still, investors...

Continue Reading
SHEIN's EU Training Push Targets Seller Compliance Gaps

Updated Category News Views 102

Chemicals buried in a cheap handbag or kids' accessory can wreck a marketplace's credibility faster than any glossy campaign can repair it. That is the uncomfortable backdrop to SHEIN and SPEAC's November 19 session on EU chemical-safety rules for marketplace sellers. This was not a fashion trend webinar; it was a practical warning about high-risk substances, regulatory...

Continue Reading
GreenTree Faces Softer Rooms, Debt and NYSE Deadline

Updated Category News Views 34

A hotel operator can post positive earnings and still leave shareholders with a nasty headache, and GreenTree's third quarter is that kind of report. NYSE:GHG produced RMB243.0 million in revenue, down 22.2% from a year earlier, while net income slipped to RMB49.3 million from RMB59.0 million. This was not a one-line stumble. Room pricing, occupancy, franchise economics...

Continue Reading
Epilepsy Campaign Puts Patient Voices Before Investors

Updated Category News Views 28

An epilepsy diagnosis can turn ordinary family routines into a maze overnight, which is why awareness work deserves more than the usual polite nod and a colored ribbon. Mediaplanet's national Epilepsy Awareness campaign, launched November 20, 2026, brings the subject into a USA TODAY print insert and related digital coverage during Epilepsy Awareness Month. That reach...

Continue Reading

Top 5 Most Recently Viewed Articles

NANO Nuclear Energy Partners with Cambridge Atom Works for ODIN Sale

Updated Category News Views 195

NANO Nuclear Energy Partners with Cambridge Atom Works for ODIN Sale NANO Nuclear Energy Inc. has made a pivotal move by signing a letter of intent to sell its innovative ODIN™ low-pressure coolant reactor technology. This strategic decision not only signifies NANO Nuclear's commitment to optimizing their technology portfolio but also enables a sharper focus on their...

Continue Reading
Project C.U.R.E. and Microsoft: Transforming Global Health Access

Updated Category News Views 244

Transforming Global Healthcare Through Innovative Partnerships In a world where access to essential healthcare is still a significant challenge, Project C.U.R.E. has teamed up with Microsoft to make a meaningful difference. This collaboration aims to change the lives of millions by providing vital medical resources to underserved populations. With over 4.5 billion people...

Continue Reading
How STRADVISION Is Leading the Charge in Automotive Innovation

Updated Category News Views 395

Transforming the Automotive Industry: STRADVISION's Role STRADVISION, a pioneer in deep learning-based vision perception technology, is at the forefront of a revolution in the automotive industry. Their latest edition of the STRADVISION Market Intelligence Report delves into significant trends transforming the automotive landscape, influenced by advancements in autonomous...

Continue Reading
Holdings and Legal Developments: Atkore Inc. Class Action Insight

Updated Category News Views 182

Understanding the Atkore Inc. Class Action Lawsuit In recent developments, Atkore Inc. (NASDAQ: ATKR) is facing a class action lawsuit that has raised significant attention among investors. The lawsuit, officially titled Westchester Putnam Counties Heavy & Highway Laborers Local 60 Benefits Fund v. Atkore Inc., highlights serious allegations against the company and its...

Continue Reading
Brenda Snow's Empowering New Book for Patients on Health Journey

Updated Category News Views 279

Brenda Snow's Inspiring Book on Navigating Health Challenges Brenda Snow's upcoming book is generating buzz as a vital resource for individuals grappling with serious health issues. This essential guide, titled Diagnosed: The Essential Guide to Navigating the Patient's Journey, is set to empower patients and caregivers alike. A Personal Narrative That Inspires In her...

Continue Reading